Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 14/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | KCNE1 | P15382 | 3/20 | 0.42 |
| ▸ | KCNQ1 | P51787 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3320921 | 1.00 | TRPV1 (0.44) | TRPV1CFTRCYP2D6CYP3A4KCNE1 | |
| SCHEMBL3321541 | 0.88 | CFTR (0.47) | TRPV1CFTRCYP2D6CYP3A4KCNE1 | |
| SCHEMBL2364748 | 0.88 | CFTR (0.47) | TRPV1CFTRCYP2D6CYP3A4KCNE1 | |
| SCHEMBL8536328 | 0.83 | TRPV1 (0.48) | TRPV1CYP2D6CYP3A4KCNE1KCNQ1 | |
| SCHEMBL3321457 | 0.82 | TRPV1 (0.42) | TRPV1CFTRCYP2D6CYP3A4KCNE1 | |
| SCHEMBL3321453 | 0.82 | TRPV1 (0.42) | TRPV1CFTRCYP2D6CYP3A4KCNE1 | |
| SCHEMBL3323847 | 0.80 | TRPV1 (0.42) | TRPV1CFTRCYP2D6CYP3A4KCNE1 | |
| SCHEMBL3323840 | 0.80 | TRPV1 (0.42) | TRPV1CFTRCYP2D6CYP3A4KCNE1 | |
| SCHEMBL3319434 | 0.78 | KCNE1 (0.44) | TRPV1CFTRCYP3A4KCNE1KCNQ1 | |
| SCHEMBL3319440 | 0.78 | KCNE1 (0.44) | TRPV1CFTRCYP3A4KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609692-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8604053-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-10 | — | — | US | disclosed |
| EP-2197426-A2 | SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND | Abbott GmbH & Co. KG (DE) | 2010-06-23 | — | — | EP | disclosed |
| US-20100137360-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-05-13 | — | — | US | disclosed |
| US-20090143423-A1 | SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND | ABBOTT GMBH & CO. KG (DE) | 2009-06-04 | — | — | US | disclosed |
| WO-2009050289-A2 | SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND | ABBOTT GMBH & CO. KG (DE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137360-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | TRPV1 1/4885CFTR 257/4885CYP2D6 878/4885 |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | TRPV1 1/4885CFTR 247/4885CYP2D6 875/4885 |
| US-20090143423-A1 | SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND | U2SURP, UMPS, HNRNPUL1 | TRPV1 4781/4885CFTR 300/4885CYP2D6 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.